FXYD1 and heart failure: The accessory protein phospholemman (PLM) activates Na/K ATPase when phosphorylated [24, 25], inhibits the enzyme when palmitoylated [26, 27], and in recent years has emerged as a drug target to correct ion transport defects associated with heart failure [28].